Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual misoprostol for reducing blood loss during abdominal myomectomy
IRCT20240922063123N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in Fibromyoma (LM) comparing Placebo with Misoprostol 400 micrograms sublingual (2 arms). Primary endpoint: Estimated intraoperative blood loss. Started Oct 2024; status: completed.
02
Drugs
misoprostol
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20240922063123N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240922063123N1.